Let's digest the proposal:The main purpose of the Meeting is to...

Let's digest the proposal:

The main purpose of the Meeting is to refresh the Company’s capacity to issue shares under ASX Listing
Rules by ratifying the prior issues of shares and options or approving the anticipated future issues of
shares and options, primarily associated with the Lind share facilities first announced on 23 June 2023.
There is also one resolution seeking ratification of the prior issues of options to Bell Potter in relation to
the Entitlement Offer announced on 25 October 2023.
In light of the cost and considerable notice period associated with holding such general meetings to be
able to ratify or approve capacity to issue equities, the Board has also included a resolution seeking
approval to issue up to 800 million shares associated with a potential placement.
The resolution provides the Board with the flexibility to rapidly make an institutional placement to
sophisticated sector focused investors, at the Board’s discretion, without the need to revert to
shareholders for approval at a further EGM and the associated delay. If approved, any shares under
such placement must be issued within three months of the Meeting. The funds raised under the
placement would support the clinical trial pipeline and otherwise for general working capital of the
Company.

That doesn't sound like a partner, just the usual CR-Sharks LIND and Bell Potter's clients. LIND squeezed extraordinary discounts out of Hopper at RAD and here already, does anyone believe they would accept a smaller discount?

Sophisticated sector focused investors, Yeah right! Seen them at IMU, RAD and here.

That's why I don't trust that way of raising, Hopper and the participants.


But if anyone sees green flags only please tell me / us.

GLTA